drugset / Trial / NCT01692691

Dacarbazine and Carmustine in Metastatic Melanoma

NCT01692691

Phase 2 Terminated 1 enrolled Western Regional Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether dacarbazine and carmustine at the doses and schedule used in this study will help to increase tumor shrinkage.

Timeline

Start
2012-08
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule Intravenous
Subject carmustine Small molecule Intravenous
Background Pegfilgrastim Protein / enzyme biologic Subcutaneous

Indications